{"rule":"For each kind, the most connected record: the count of distinct records linking to or from it, ties broken by the length of its own prose. The next two by the same rule are the runners-up.","schedule":"Day of the year (reader's local date) modulo the kinds list picks the kind; ?spotlight=<kind> on the home page overrides it.","kinds":["cancer","drug","trial","technology","target","idea","roadmap","person","institution","company","paper","collection","pairing","bottleneck"],"buildKind":"company","sets":{"cancer":{"kind":"cancer","label":"cancers","hero":{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","tldr":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story.","facts":[{"kicker":"State of the art","text":"5-year PFS 60% with lorlatinib in ALK+ disease."},{"kicker":"Newest","text":"Zongertinib first line; zidesamtinib (ROS1) approved; divarasib beats first-generation KRAS inhibitors; neladalkib and ivonescimab under FDA review"},{"kicker":"Open problem","text":"Screening uptake is under 20% in the US and lower elsewhere; never-smoker adenocarcinoma has no screening pathway."}],"pills":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"}],"connected":2027},"runnersUp":[{"id":"colorectal","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"prostate","name":"Prostate cancer","route":"/cancers/prostate/"}]},"drug":{"kind":"drug","label":"Treatments & tests","hero":{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","tldr":"Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised…","facts":[{"kicker":"Mechanism","text":"Humanised IgG4 blocking PD-1; restores T-cell effector function."},{"kicker":"Latest approval","text":"2026, US: Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC"},{"kicker":"Modality","text":"Monoclonal antibody (anti-PD-1)"}],"pills":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"connected":843},"runnersUp":[{"id":"carboplatin","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","name":"Cisplatin","route":"/drugs/cisplatin/"}]},"trial":{"kind":"trial","label":"trials","hero":{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","tldr":"The trial that added immunotherapy to pre-surgery chemotherapy for triple-negative breast cancer and, uniquely, improved survival.","facts":[{"kicker":"Design","text":"Phase 3; Early-stage (II-III) TNBC: pembrolizumab + chemotherapy before surgery, pembrolizumab after"},{"kicker":"Result","text":"EFS HR 0.63; OS HR 0.66 (5-year); 7-year OS 85.1% vs 77.2%."},{"kicker":"Enrolled","text":"1,174 participants, sponsored by Merck"}],"pills":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"connected":72},"runnersUp":[{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/"},{"id":"stampede","name":"STAMPEDE","route":"/trials/stampede/"}]},"technology":{"kind":"technology","label":"technologies","hero":{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","tldr":"Immune checkpoint inhibitors are antibodies against CTLA-4, PD-1 or PD-L1 that release the brakes on T cells so they attack the cancer. They are approved in more than 20 tumour types and produce lasting, sometimes curative responses that chemotherapy rarely does, but most patients do not respond and autoimmune side effects are the cost.","facts":[{"kicker":"Principle","text":"Blocking inhibitory receptor-ligand interactions restores T-cell priming (CTLA-4) and effector function (PD-1)."},{"kicker":"Strength","text":"Durable, sometimes curative responses"},{"kicker":"Limitation","text":"Most patients do not respond"}],"pills":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"connected":1640},"runnersUp":[{"id":"cytotoxic-chemotherapy","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kinase-inhibitors","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}]},"target":{"kind":"target","label":"targets","hero":{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","tldr":"PD-1 is a brake on T cells. Blocking it releases the immune system against the tumour and has cured some previously incurable cancers.","facts":[{"kicker":"Biology","text":"Inhibitory receptor on activated T cells; ligands PD-L1/PD-L2. Tumour PD-L1 expression, TMB, and MSI predict response imperfectly."},{"kicker":"Where found","text":"Exhausted T cells in the tumour microenvironment"},{"kicker":"Class","text":"checkpoint"}],"pills":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"connected":394},"runnersUp":[{"id":"her2","name":"HER2","route":"/targets/her2/"},{"id":"kras","name":"KRAS","route":"/targets/kras/"}]},"idea":{"kind":"idea","label":"ideas","hero":{"id":"idea-prostate-hrr-testing-at-metastatic-diagnosis","kind":"idea","name":"Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later","route":"/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/","tldr":"About one man in eight with prostate cancer that has spread carries an inherited DNA repair fault, and about one in five has one in the tumour. The drugs for those faults have moved to the beginning of treatment, but the test is still usually done near the end, when it is too late to use the result.","facts":[{"kicker":"Hypothesis","text":"Reflex germline and tumour homologous recombination repair testing at the moment of metastatic diagnosis, rather than on clinician request at castration resistance, increases the proportion of eligible men who receive a PARP inhibitor in…"},{"kicker":"Proposed test","text":"A stepped-wedge implementation trial across cancer networks, switching from clinician-requested testing to a reflex order fired by the coding of metastatic prostate cancer. Co-primary outcomes: the proportion of men with a homologous…"},{"kicker":"Maturity","text":"early clinical; actor: clinic"}],"pills":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"}],"connected":40},"runnersUp":[{"id":"idea-prostate-randomise-the-sequence-not-only-the-drugs","name":"Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer","route":"/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/"},{"id":"idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine","name":"Watch for the cancer changing cell type before the biopsy says neuroendocrine, and act on it","route":"/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/"}]},"roadmap":{"kind":"roadmap","label":"roadmaps","hero":{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/","tldr":"Lymphoma was the first cancer shown to be caused by a virus, the first common cancer sorted into subtypes by reading which genes were switched on, and the first in which a patient's own immune cells were reprogrammed to cure them. This roadmap follows the evidence from 1958 to the trials reading out in 2032.","facts":[{"kicker":"Steps","text":"11 steps, starting 1958-1981: Two viruses, found because lymphoma is the cancer you can get hold of"},{"kicker":"Now","text":"Four things no trial on this page has fixed"},{"kicker":"Next","text":"What the registry says is coming"}],"pills":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"connected":263},"runnersUp":[{"id":"tnbc-roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"},{"id":"pancreatic-roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}]},"person":{"kind":"person","label":"people","hero":{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","tldr":"Bert Vogelstein is the most-cited scientist in cancer genetics: he mapped how colorectal cancer develops and founded the field of cancer genome sequencing and blood-based detection.","facts":[{"kicker":"Role","text":"Clayton Professor of Oncology; Co-Director, Ludwig Center; HHMI Investigator"},{"kicker":"Specialisms","text":"Cancer genetics, Colorectal tumorigenesis, Liquid biopsy, Early detection"},{"kicker":"Papers","text":"7 listed"}],"pills":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"},{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"}],"connected":41},"runnersUp":[{"id":"eric-van-cutsem","name":"Eric Van Cutsem","route":"/people/eric-van-cutsem/"},{"id":"eileen-oreilly","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/"}]},"institution":{"kind":"institution","label":"institutions","hero":{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/","tldr":"The network of European cancer centres that runs the accreditation and designation programme awarding 'Comprehensive Cancer Centre' status.","facts":[{"kicker":"Where","text":"Brussels, BE"},{"kicker":"Type","text":"consortium"},{"kicker":"Programmes","text":"Accreditation and Designation Programme, Working groups (economics, biobanking, digital), EU cancer infrastructure projects"}],"pills":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"},{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/"},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"},{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/"},{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/"},{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/"}],"connected":284},"runnersUp":[{"id":"nci","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"mskcc","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}]},"company":{"kind":"company","label":"companies","hero":{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","tldr":"AstraZeneca is the most ADC-committed large pharma, co-owner of Enhertu and Datroway, with deep targeted-therapy and radiopharma bets.","facts":[{"kicker":"Headquarters","text":"Cambridge"},{"kicker":"Type","text":"pharma"},{"kicker":"Ticker","text":"AZN"}],"pills":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"connected":408},"runnersUp":[{"id":"merck","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"bms","name":"Bristol Myers Squibb","route":"/companies/bms/"}]},"paper":{"kind":"paper","label":"key papers","hero":{"id":"paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","kind":"paper","name":"SU2C-PCF: integrative clinical genomics of advanced prostate cancer","route":"/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/","tldr":"One hundred and fifty men with prostate cancer that had spread and stopped responding to hormones had their tumours biopsied and sequenced prospectively. Nine in ten had a genetic change that a drug could in principle be aimed at, and one in five had a broken DNA repair gene.","facts":[{"kicker":"Finding","text":"Aberrations of the androgen receptor, ETS genes, TP53 and PTEN were frequent, in 40 to 60 percent of cases, with TP53 and androgen receptor alterations enriched in metastatic castration-resistant disease compared with primary prostate…"},{"kicker":"What it means","text":"The genomic definition of advanced prostate cancer, and the evidence that made molecular testing standard in it. The 19.3 percent DNA repair figure is the direct ancestor of PROfound, TRITON3, PROpel and TALAPRO-2, and the 8 percent…"},{"kicker":"Published","text":"Cell, 2015"}],"pills":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"}],"connected":46},"runnersUp":[{"id":"paper-flaura-nejm-2018","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/"},{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/"}]},"collection":{"kind":"collection","label":"collections","hero":{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/","tldr":"Open Targets scores how strongly each gene is linked to each disease, with the evidence behind it.","facts":[{"kicker":"Holds","text":"Target-disease association evidence integrating genetics, expression, literature, and drugs."},{"kicker":"Maintainer","text":"EMBL-EBI, Sanger, GSK, Sanofi, BMS, Pfizer, Genentech"},{"kicker":"Licence","text":"CC0 / open"}],"pills":[{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"},{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/"},{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/"},{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/"}],"connected":1055},"runnersUp":[{"id":"intogen","name":"IntOGen","route":"/collections/intogen/"},{"id":"civic","name":"CIViC","route":"/collections/civic/"}]},"pairing":{"kind":"pairing","label":"pairings","hero":{"id":"proton-vs-imrt","kind":"pairing","name":"Caution: proton therapy vs IMRT","route":"/pairings/proton-vs-imrt/","tldr":"Protons stop inside the tumour; modern X-ray beams (IMRT) still exit through healthy tissue. That physical difference only matters if it changes cure or late harm enough to justify the cost, which randomised adult trials have not settled.","facts":[{"kicker":"Rationale","text":"No exit dose and a distal LET rise can spare a late-responding organ or, if the edge sits in that organ, harm it. Alpha/beta of tumour versus late tissue decides whether that physical difference is biologically large."},{"kicker":"Evidence","text":"Paediatric and skull-base use is established on integral-dose grounds. Adult randomised evidence is mixed and still accruing (PARTIQoL, RADCOMP, NRG oesophagus and lung)."},{"kicker":"Type","text":"caution"}],"pills":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/"}],"connected":20},"runnersUp":[{"id":"ctdna-mrd-to-adjuvant","name":"ctDNA MRD → adjuvant therapy decision","route":"/pairings/ctdna-mrd-to-adjuvant/"},{"id":"btki-plus-venetoclax-fixed-duration","name":"BTK inhibitor + venetoclax, fixed duration","route":"/pairings/btki-plus-venetoclax-fixed-duration/"}]},"bottleneck":{"kind":"bottleneck","label":"bottlenecks","hero":{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","tldr":"Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.","facts":[{"kicker":"Cause","text":"Regulatory approval and pricing are based on efficacy endpoints, so sponsors invest little in quality-of-life measurement."},{"kicker":"Current efforts","text":"PRO-CTCAE (NCI) provides a validated patient-reported version of the toxicity scale now used in many trials."},{"kicker":"Success looks like","text":"Every registrational oncology trial collects and publishes patient-reported outcomes with the primary results, quality of life is graded in every value framework and reimbursement decision, and discontinuation for toxicity on chronic oral…"}],"pills":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"connected":375},"runnersUp":[{"id":"b-survivorship","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"},{"id":"b-global-access","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"}]}}}